Catalyst calendar
Monthly and list views
Filters
Monthly view
Jun 28
GMAB
Conference update on combination cohorts
Approved/Phase 3ASCO
Jul 10
RVMD
RAS(ON) inhibitor expansion cohort update
Phase 2Phase 2 Readout
Jul 24
ALLO
Cell therapy pipeline investor update
Phase 2Investor Day
Aug 15
RCUS
STAR-221 interim analysis window
Phase 3Phase 3 Readout
Sep 30
EXEL
STELLAR pivotal study top-line data
Phase 3Phase 3 Readout
Oct 1
MRUS
Combination cohort clinical update
Phase 2Phase 2 Readout
Nov 20
NUVL
Potential regulatory action window
RegistrationFDA PDUFA
Dec 15
AVBP
ClinicalTrials.gov primary completion watch
Phase 3Clinical Trial Completion
List view
| Company | Catalyst | Asset | Phase | Expected | Confidence | Status |
|---|---|---|---|---|---|---|
| GMAB Genmab | Conference update on combination cohorts ASCO | Epcoritamab | Approved/Phase 3 | ASCO 2026 | exact | upcoming |
| RVMD Revolution Medicines | RAS(ON) inhibitor expansion cohort update Phase 2 Readout | RMC-6236 | Phase 2 | July 2026 | month | active |
| ALLO Allogene Therapeutics | Cell therapy pipeline investor update Investor Day | Cema-cel | Phase 2 | July 24, 2026 | exact | upcoming |
| RCUS Arcus Biosciences | STAR-221 interim analysis window Phase 3 Readout | Domvanalimab | Phase 3 | Q3 2026 | quarter | upcoming |
| EXEL Exelixis | STELLAR pivotal study top-line data Phase 3 Readout | Zanzalintinib | Phase 3 | 2H 2026 | half year | upcoming |
| MRUS Merus | Combination cohort clinical update Phase 2 Readout | Petosemtamab | Phase 2 | Q4 2026 | quarter | upcoming |
| NUVL Nuvalent | Potential regulatory action window FDA PDUFA | Zidesamtinib | Registration | Q4 2026 | quarter | upcoming |
| AVBP ArriVent BioPharma | ClinicalTrials.gov primary completion watch Clinical Trial Completion | Furmonertinib | Phase 3 | December 2026 | month | active |